Clene closes USD 4 million registered direct share offering led by insiders
CLNN•Clene closes insider-led share offering
Clene closed a registered direct offering of common stock to existing shareholders, raising USD 4 million in gross proceeds.
- The financing was priced at the market under Nasdaq rules.
- No placement agent or underwriter was used.
- Cash is expected to fund operations through mid-first quarter 2027, beyond a potential FDA decision on CNM-Au8 NDA review acceptance.
- FDA acceptance could also trigger USD 6.7 million to USD 7.8 million from common stock warrants issued in a January 2026 financing.
